Drug intelligence / Profile preview

N-acetyl cysteine + glutathione

Development stage
Preclinical
Lead developer
Galectin Therapeutics
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

N-acetyl cysteine + glutathione is a combination of two antioxidant compounds frequently used as a dietary supplement or in intravenous infusion therapy. N-acetyl cysteine (NAC) is an acetylated derivative of the amino acid L-cysteine and serves as a precursor to the endogenous antioxidant glutathione. Glutathione itself is a tripeptide composed of glutamate, glycine, and cysteine, and plays a central role in cellular redox balance by neutralizing free radicals and supporting detoxification processes. The rationale for combining NAC with glutathione lies in their synergistic effects on enhancing the body's antioxidant defenses. NAC increases intracellular levels of cysteine, which can be rate-limiting for de novo synthesis of glutathione during oxidative stress[4][6]. Supplementation with both may provide more robust support against oxidative damage than either alone[2]. This combination has been explored for potential benefits such as reducing fatigue, improving immune function, supporting liver health (especially in cases like acetaminophen toxicity), aiding respiratory conditions by acting as mucolytics, and possibly providing neuroprotective effects[2][4][6]. Mechanistically: - NAC acts primarily by replenishing intracellular stores of cysteine to boost endogenous synthesis of reduced (active) glutathione. - Glutathione directly scavenges reactive oxygen species (ROS), supports detoxification enzymes such as glutathione peroxidase, reduces inflammation via modulation of cytokines like IL-6 or TNFα, and helps maintain mitochondrial function[4]. This combination is most commonly available as an over-the-counter dietary supplement or administered intravenously at wellness clinics.

Other names
NAC + glutathioneN-acetylcysteine and glutathione combination
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SLC7A11 (Cystine-Glutamate Antiporter)AMPAR (AMPA receptor)Glutamate receptor, ionotropic, NMDA-type – redox site

Beyond the preview

Go deeper on N-acetyl cysteine + glutathione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-acetyl cysteine + glutathione.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call